The observation that traditional efficacy prediction indicators do not match the response to blinatumomab is consistent with the fact that blinatumomab works by CD3/CD19 bispecific targeting to lyse tumor cells, thereby bypassing many mechanisms associated with chemotherapy resistance (32). The gene discussed is CD19; the disease is neoplasm.